Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Importantly, the combination of giredestrant and everolimus was well tolerated
Subscribe To Our Newsletter & Stay Updated